The company also recently earned regulatory approval in the U.S. for mFLUSIVA, an influenza vaccine, a niche where it should ...

(This Aug 28 story has been repeated with no changes to text.) By Bhanvi Satija and Sriparna Roy Aug 28 (Reuters) - BioNTech ...

BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...

The company is coming back into the spotlight thanks to recent developments.

A vaccine manufacturer has said it is terminating a clinical trial testing an experimental vaccine against cancer. The vaccine, which utilizes messenger ribonucleic acid (mRNA) technology, is made by ...

BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's ...

BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a ...

Updated COVID vaccines are necessary, just as flu vaccines are updated because immunity wanes with time, even among those ...

Moderna (MRNA), and Merck (MRK) fall after a mid-stage trial setback for a cancer shot developed by BioNTech (BNTX) and Roche ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...